You searched for "imaging"

897 results found

Testicular cancer (Mar 2015)

Case 1 What does the ultrasound show? What further imaging does this patient require? Which tumour markers should be checked? What is the half-life of these markers? What does an elevation in these markers mean? Case 2 What is this...

Onco-fertility: a review

Subfertility or infertility is a major problem affecting men diagnosed with testicular cancer (TC) either due to the disease itself [1], or as a result of management [2]. TC is the most prevalent cancer affecting men of reproductive age [3]....

Femeda Ltd Wins Prestigious Medilink Partnership with Academia Award

Partnership with Academia Award Winner: Femeda Ltd Femeda has committed to the first real world clinical trial for a consumer medical device globally to be run in Manchester. Femeda is extending the partnership with engagement of Phd students from the...

Femeda Ltd Wins Prestigious Medilink Partnership with Academia Award

Femeda has committed to the first real world clinical trial for a consumer medical device globally to be run in Manchester. Femeda is extending the partnership with engagement of Phd students from...

RSM: Endourology Day 2027

Why attend? Gain practical updates on current best practice in endourology and stone disease management Explore how artificial intelligence and digital tools are beginning to influence clinical decision-making and patient pathways in endourology Learn how quality improvement initiatives are shaping...

Keeping your eye on the ball: atypical presentations of testicular malignancy

Most testicular cancers present with a painless lump on the testes, and most are confidently diagnosed on examination and ultrasound. They have an excellent prognosis, with 90% patients alive at 10 years [1]. However, advanced testicular cancer, or those with...

Technology for remote working and COVID-19 resources

The COVID-19 pandemic has altered every aspect of how we live, and how healthcare needs to be provided for the welfare of patients and staff. I thought I would try to summarise a few potential technology tools that could be...

Training to be a urologist: how risky is it?

The NHS and urology face challenging times in trying to provide quality patient care efficiently and economically. Urology trainees are experiencing conflicting pressures with a new contract, a challenging on-call system and changing training requirements in an overstretched, centralised service...

Increasing PSA after negative prostate biopsy - solving the clinical puzzle

There are standard guidelines for first transrectal ultrasonography (TRUS) guided biopsy in a patient presenting with elevated prostate-specific antigen (PSA) or suspicious digital rectal examination (DRE) findings. Patients are generally warned before a TRUS biopsy in respect of a false...

Defining adjuvant, consolidative, and salvage treatment after RP

The most common oncologic outcome following radical prostatectomy (RP) for localised prostate cancer is achieving undetectable prostate-specific antigen (PSA) levels (<0.1 ng/ml), indicating an absence of detectable disease. However, the landscape of RP is shifting as active surveillance becomes the...

26th Asia-Pacific Prostate Cancer Conference (APCC2026)

Prostate cancer continues to represent a major global health challenge, profoundly impacting the lives of men and their families every day. Yet, over the past decade, transformative advances have changed the landscape of prostate cancer management enabling men to live...

Immunotherapy in renal cancer

Renal cell carcinoma (RCC) is the sixth most common solid organ cancer in the UK. In 2018, there were 403,262 people diagnosed worldwide with the disease (2.2% of all cancer cases), and it accounted for 175,098 deaths in total (1.8%...